Pacer Advisors Inc. Buys 11,602 Shares of Illumina, Inc. $ILMN

Pacer Advisors Inc. boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.5% in the 1st quarter, Holdings Channel reports. The institutional investor owned 475,235 shares of the life sciences company’s stock after buying an additional 11,602 shares during the quarter. Pacer Advisors Inc.’s holdings in Illumina were worth $58,577,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Empowered Funds LLC boosted its stake in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new stake in Illumina in the 2nd quarter worth about $621,000. CW Advisors LLC purchased a new stake in Illumina in the 2nd quarter worth about $275,000. Marshall Wace LLP lifted its stake in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC boosted its position in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after buying an additional 1,748 shares during the period. Institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,004,384 shares of company stock worth $155,833,908 over the last three months. Corporate insiders own 2.90% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Raised revenue outlook and clinical-sequencing demand support the stock. Illumina reported second-quarter revenue of $1.159 billion, up from $1.059 billion a year earlier, and raised its 2026 revenue forecast to $4.60 billion-$4.64 billion. Management’s focus on clinical sequencing and multi-omics is reinforcing expectations for continued growth. Why Illumina Is Up After Raising 2026 Revenue Outlook
• Positive Sentiment: Analysts raised their valuation expectations. Piper Sandler reaffirmed its “overweight” rating and increased its price target to $225 from $200. Other recent reports cited price targets of $210 and $230, indicating that some analysts see additional upside despite the stock’s recent rally. Piper Sandler Rating Report Illumina Price Target Raised to $210 Illumina Price Target Raised to $230
• Neutral Sentiment: Momentum is strong, but investors are questioning how much upside remains. ILMN reached a fresh 52-week high after more than doubling over the past year. The move reflects improving fundamentals, but the elevated share price increases sensitivity to any execution or guidance disappointment. Illumina Hits Fresh High
• Negative Sentiment: Valuation and cash-flow concerns could weigh on returns. One analysis estimates the shares may be approximately 19% overvalued, while another notes that market multiples appear expensive even though a discounted-cash-flow model suggests potential upside. Broader concerns include whether strong cash generation will translate into efficient spending and sustained growth. Illumina Could Be Overvalued Cash-Producing Stocks That Concern Us
• Negative Sentiment: An insider sold shares. Scott M. Davies sold 615 shares worth $123,000 under a pre-arranged Rule 10b5-1 plan. The sale was relatively small and leaves him with 20,338 shares, but it is still a modest negative signal for sentiment.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Guggenheim upped their target price on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday. Royal Bank Of Canada upped their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $188.40.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $198.16 on Tuesday. The firm has a market cap of $29.98 billion, a PE ratio of 36.97, a price-to-earnings-growth ratio of 2.94 and a beta of 1.44. The firm’s 50 day simple moving average is $177.78 and its 200-day simple moving average is $147.61. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.37 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.